COIOSDeep risk insights through multi-disciplinary research across the globe
pile of gray plastic folding chairs on gray concrete flooring
Item new Preprint · not peer-reviewed Added

Black patients were 4% of enrolment in the defining hypertrophic cardiomyopathy trials

Across 13 of the trials that define current treatment of hypertrophic cardiomyopathy, Black patients were 3.98% of Black and White participants, as compared to 16.5% of US adults.

The authors pooled race data from 13 of the trials that define current treatment of hypertrophic cardiomyopathy, covering 1,780 Black or White participants. Black patients were 3.98% of those participants, as compared to 16.5% of the US adult population. Where the trial sites sat predicted 26.4% Black enrolment, and Black adults less often meeting numerical entry criteria explained only 2.0% of the gap.

Why it is interesting: The disease is at least as common in Black Americans, yet neither site location nor entry criteria explains the shortfall.

Source
medRxiv, 27 September 2026
Paper
Race and ethnicity in the landmark hypertrophic cardiomyopathy trials: representation against population, site-catchment, and disease-referenced expectations
Authors
Wescott AP, Petek BJ, O’Sullivan JW, Moussavi-Harami F, Owens D, Lawrie A et al.
DOI
10.64898/2026.09.24.26363977
Type
Preprint
Design
Meta-analysis of participant demographics from 13 of 32 landmark interventional hypertrophic cardiomyopathy trials (1,780 Black or White participants), with geospatial site-catchment and NHANES eligibility modelling
Verdict
New finding
Driver
Heart and stroke

Other drivers in Health today